| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Anti-phosphatidylethanolamine (aPE) Antibodies: a Survey
|
Mcintyre, John A
|
|
2000
|
15 |
2 |
p. 185-193
9 p.
|
artikel
|
| 2 |
Antiphospholipid Antibodies and the Protein C Pathway
|
Esmon, Naomi L
|
|
2000
|
15 |
2 |
p. 221-225
5 p.
|
artikel
|
| 3 |
Antiphospholipid Antibodies, Malignancies and Paraproteinemias
|
Asherson, Ronald A.
|
|
2000
|
15 |
2 |
p. 117-122
6 p.
|
artikel
|
| 4 |
Antiphospholipid Antibody-mediated Disruption of the Annexin-V Antithrombotic Shield: a Thrombogenic Mechanism for the Antiphospholipid Syndrome
|
Rand, Jacob H
|
|
2000
|
15 |
2 |
p. 107-111
5 p.
|
artikel
|
| 5 |
Antiphospholipid Syndrome and Heparin-induced Thrombocytopenia: Update on Similarities and Differences
|
Gruel, Yves
|
|
2000
|
15 |
2 |
p. 265-268
4 p.
|
artikel
|
| 6 |
Apoptosis and the Antiphospholipid Syndrome
|
Rauch, Joyce
|
|
2000
|
15 |
2 |
p. 231-235
5 p.
|
artikel
|
| 7 |
Conceptions and Misconceptions in Testing for Lupus Anticoagulants
|
Exner, Thomas
|
|
2000
|
15 |
2 |
p. 179-183
5 p.
|
artikel
|
| 8 |
Differential Diagnosis of Central Nervous System Manifestations of the Antiphospholipid Antibody Syndrome
|
Brey, Robin L
|
|
2000
|
15 |
2 |
p. 133-138
6 p.
|
artikel
|
| 9 |
Do we Know which Patients with the Antiphospholipid Syndrome Should Receive Long-term High Dose Anti-coagulation?
|
Derksen, Ronald H.W.M
|
|
2000
|
15 |
2 |
p. 255-259
5 p.
|
artikel
|
| 10 |
Endothelial Activation by aPL: A Potential Pathogenetic Mechanism for the Clinical Manifestations of the Syndrome
|
Meroni, P.L
|
|
2000
|
15 |
2 |
p. 237-240
4 p.
|
artikel
|
| 11 |
Epidemiology of the Antiphospholipid Antibody Syndrome
|
Petri, Michelle
|
|
2000
|
15 |
2 |
p. 145-151
7 p.
|
artikel
|
| 12 |
Epitope Studies with Anti-β2-glycoprotein I Antibodies from Autoantibody and Immunized Sources
|
Reddel, Stephen W
|
|
2000
|
15 |
2 |
p. 91-96
6 p.
|
artikel
|
| 13 |
‘Equivocal’ Antiphospholipid Syndrome
|
Harris, E.Nigel
|
|
2000
|
15 |
2 |
p. 81-85
5 p.
|
artikel
|
| 14 |
Ethnicity and APS
|
Wilson, Wendell A
|
|
2000
|
15 |
2 |
p. 153-155
3 p.
|
artikel
|
| 15 |
Experimental Thrombosis and Antiphospholipid Antibodies: New Insights
|
Pierangeli, Silvia S
|
|
2000
|
15 |
2 |
p. 241-247
7 p.
|
artikel
|
| 16 |
Future Trends for Treatment of APS
|
Lockshin, Michael D
|
|
2000
|
15 |
2 |
p. 261-264
4 p.
|
artikel
|
| 17 |
β2-glycoprotein I–anti-β2-glycoprotein I Interaction
|
Koike, Takao
|
|
2000
|
15 |
2 |
p. 97-100
4 p.
|
artikel
|
| 18 |
Heat Shock Protein 60/65, β2-glycoprotein I and Oxidized LDL as Players in Murine Atherosclerosis
|
Shoenfeld, Yehuda
|
|
2000
|
15 |
2 |
p. 199-202
4 p.
|
artikel
|
| 19 |
Hormonal Contraception and Replacement and the Use of Androgens in the Antiphospholipid Syndrome
|
Lahita, Robert G.
|
|
2000
|
15 |
2 |
p. 213-216
4 p.
|
artikel
|
| 20 |
Kidney Involvement in the Antiphospholipid Syndrome
|
Nochy, Dominique
|
|
2000
|
15 |
2 |
p. 127-132
6 p.
|
artikel
|
| 21 |
Long-term Prognosis of Antiphospholipid Syndrome in Patients with Systemic Lupus Erythematosus
|
Alarcón-Segovia, Donato
|
|
2000
|
15 |
2 |
p. 157-161
5 p.
|
artikel
|
| 22 |
Management of Patients with Antiphospholipid Antibodies Undergoing In Vitro Fertilization
|
Udoff, Laurence C
|
|
2000
|
15 |
2 |
p. 209-211
3 p.
|
artikel
|
| 23 |
New Developments in Viral Peptides and APL Induction
|
Gharavi, Azzudin E
|
|
2000
|
15 |
2 |
p. 227-230
4 p.
|
artikel
|
| 24 |
Obstetric Management of Antiphospholipid Syndrome
|
Rai, Raj
|
|
2000
|
15 |
2 |
p. 203-207
5 p.
|
artikel
|
| 25 |
Overview on Anticardiolipin ELISA Standardization
|
Tincani, Angela
|
|
2000
|
15 |
2 |
p. 195-197
3 p.
|
artikel
|
| 26 |
Primary Prevention of Thrombosis in Subjects with Positive Antiphospholipid Antibodies
|
Khamashta, Munther A
|
|
2000
|
15 |
2 |
p. 249-253
5 p.
|
artikel
|
| 27 |
Recent Advances in Antiphospholipid Antibody-related Valvulopathies
|
Cervera, Ricard
|
|
2000
|
15 |
2 |
p. 123-125
3 p.
|
artikel
|
| 28 |
Should we Include Anti-prothrombin Antibodies in the Screening for the Antiphospholipid Syndrome?
|
Galli, Monica
|
|
2000
|
15 |
2 |
p. 101-105
5 p.
|
artikel
|
| 29 |
Speculations on APS in the Coming Millennium
|
Hughes, Graham
|
|
2000
|
15 |
2 |
p. 269-271
3 p.
|
artikel
|
| 30 |
Structure–Function Studies on β2-glycoprotein I
|
de Groot, Philip G
|
|
2000
|
15 |
2 |
p. 87-89
3 p.
|
artikel
|
| 31 |
The Anticoagulant and Anti-inflammatory Roles of the Protein C Anticoagulant Pathway
|
Esmon, Charles T
|
|
2000
|
15 |
2 |
p. 113-116
4 p.
|
artikel
|
| 32 |
The Mystery of Sneddon Syndrome: Relationship with Antiphospholipid Syndrome and Systemic Lupus Erythematosus
|
Francès, C
|
|
2000
|
15 |
2 |
p. 139-143
5 p.
|
artikel
|
| 33 |
Tissue Factor Pathway and the Antiphospholipid Syndrome
|
Roubey, Robert A.S
|
|
2000
|
15 |
2 |
p. 217-220
4 p.
|
artikel
|
| 34 |
Use of the Dilute Russell Viper Venom Time (dRVVT): Its Importance and Pitfalls
|
Triplett, Douglas A
|
|
2000
|
15 |
2 |
p. 173-178
6 p.
|
artikel
|
| 35 |
Which are the Best Biological Markers of the Antiphospholipid Syndrome?
|
Carreras, Luis O
|
|
2000
|
15 |
2 |
p. 163-172
10 p.
|
artikel
|
Tijdschrift beschrijving